Clinical trial NCT00086671: Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS)
Official title: A 24-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose Finding, Safety, Tolerability, and Efficacy Study of the Human Anti-IL-12 Antibody ABT-874 in Subjects With Multiple Sclerosis With a 24-Week Double-Blind, Active Extension Phase
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Multiple Sclerosis
Lead sponsor: AbbVie
Sponsor class: INDUSTRY
First posted: 2004-07-09
Enrollment: 215
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The objective of the trial is to study the safety and effectiveness of ABT-874 administered weekly or every other week in patients with relapsing remitting and secondary progressive multiple sclerosis as compared to placebo. Effectiveness will be measured based on MRI scans done periodically throughout the study.

Detailed description: This study was done in subjects with relapsing remitting MS or secondary progressive MS with the objective of assessing the safety and efficacy of 200 mg of ABT-874 weekly or QOW versus placebo. There were 3 phases to the study, 24 week double blind followed by 24 weeks of an active extension, followed by 48 weeks of double blind active extension. The trial was discontinued by Abbott in Aug 2006.

Eligibility criteria: Inclusion Criteria:

* Age between 18 and 55 years
* Diagnosis of active relapse within 12 months of screening.
* At least one relapse within 12 months of screening.
* Must be able to walk at least 65 feet with or without assistance
* Off Copaxone or interferon therapy for two months prior to screening
* Able and willing to learn to self-administer weekly injections, or have a designee who will administer study medication
* Female participants must use contraceptives while on study drug

Exclusion Criteria:

* Primary progressive multiple sclerosis (PPMS)
* Immunosuppressive therapy (such as azathioprine, methotrexate (MTX), but excluding corticosteroids) within six months of randomization. Subjects with previous treatment with cyclophosphamide, total lymphoid irradiation, mitoxantrone, cladribine, or bone marrow transplantation, regardless of duration, will be excluded from participation in this study
* Systemic corticosteroid therapy within four weeks prior to the first screening Magnetic Resonance Imaging (MRI)
* Participation in any clinical study, whether or not it involves an investigational drug within three months prior to the screening visit
* Use of any investigational drug with disease-modifying potential for the treatment of multiple sclerosis (MS) within six months of randomization (prior use of investigational agents for the symptomatic treatment of MS, e.g., 4-aminopyridine (4-AP), may be allowed following discussion with medical monitor
* Concomitant statin use in doses exceeding the manufacturers' maximum recommended daily dosages for treatment of hypercholesterolemia or as part of an MS disease-modifying protocol
* Infection or risk factors for severe infections
* Excessive immunosuppression or other factors associated with it, including human immunodeficiency virus (HIV) infection
* Severe, recurrent, or persistent infections \[such as Hepatitis B or C, or borreliosis or recurrent urinary tract infection (UTI) (\> 3 UTIs requiring antibiotic treatment per year) or recurrent pneumonia (\> 2 pneumonias requiring antibiotic treatment per year) or infected decubitus ulcers\]
* Evidence of current inactive tuberculosis (TB) infection; recent exposure to mycobacterium tuberculosis (converters to a positive purified protein derivative \[PPD\]). Subjects with a positive PPD or a chest X-ray suggestive of prior TB infection will be excluded
* Active tuberculosis disease
* Active chronic Lyme disease
* Active syphilis
* Any other significant infection requiring hospitalization or intravenous (IV) antibiotics in the month prior to Screening; or
* Infection requiring treatment with antibiotics in the two weeks prior to Screening.
* Any of the following risk factors for development of malignancy:

  * History of lymphoma or leukemia
  * Cutaneous squamous-cell or basal cell carcinoma (EXCEPT if treated more that two years prior to Screening with evidence of recurrence or residual disease)
  * Other malignancy (EXCEPT if treated more than five years prior to Screening without evidence of recurrence or residual disease) or
  * Disease associated with an increased risk of malignancy (such as familial polyposis).
* History of major immunologic reaction (such as serum sickness or anaphylactoid reaction) to an Immunoglobulin G (IgG) containing agent (such as intravenous (IV) gamma globulin, a fusion protein, or monoclonal antibody)
* Confounders of the assessment of neurologic response including other diseases that produce chronic neurologic manifestations (such as amyotrophic lateral sclerosis, Guillain-Barre syndrome, Lyme disease, myasthenia gravis, etc.)
* Prior exposure to anti-IL-12 antibodies
* Confounders of safety assessment, such as an unstable medical condition not related to MS (including those requiring an adjustment of treatment in the four weeks prior to Screening)
* Exacerbation of asthma requiring hospitalization in the ten years prior to Screening (subjects with asthma not requiring hospitalization should be discussed with the medical monitor prior to Screening)
* Pregnant or lactating females
* The following exclusionary laboratory values at screening or baseline:

  * Hemoglobin (Hgb) \<10 g/dL in females or \<12 g/dL in males;
  * White blood cell (WBC) count \<3 x 109/L;
  * Platelet count \<100 x 109/L
  * Serum aspartate transaminase (AST) or alanine transaminase (ALT) x 3 upper limits of normal (ULN);
  * Serum total bilirubin \>/= 3 mg/dL (\>/= 51 x mol/L)
  * Serum creatinine \>1.6 mg/dL (\> 141 x mol/L)
* Subject has a recent history of substance abuse or psychiatric illness that could preclude compliance with the protocol
* In the eight weeks prior to study drug administration, the subject has received a transfusion of any blood product, or has had 500 mL or more of blood removed by repetitive or one-time blood donation, plasmapheresis, or plasma exchange, or has lost 550 mL or more blood because of hemorrhage; or
* For any reason, subject is considered by the investigator to be an unsuitable candidate to receive ABT-874.

Primary outcomes:
measure: Comparison of the cumulative number of Gd enhanced (T1 weighted) lesions during the treatment phase
timeFrame: 24 weeks
measure: Safety and clinical laboratory parameters
timeFrame: monthly
measure: vital signs
timeFrame: monthly
Secondary outcomes:
measure: Magnetic Resonance Imaging endpoints
timeFrame: Screening
measure: Magnetic Resonance Imaging endpoints
timeFrame: Baseline (Week 0)
measure: Magnetic Resonance Imaging endpoints
timeFrame: Every 4 weeks after baseline through Week 24
measure: Magnetic Resonance Imaging endpoints
timeFrame: Every 12 weeks from Week 26 to Week 120
measure: Magnetic Resonance Imaging endpoints
timeFrame: Early Termination
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Site Reference ID/Investigator# 107
state: Arizona
city: Sun City
country: United States
facility: Site Reference ID/Investigator# 163
state: Arizona
city: Little Rock
country: United States
facility: Site Reference ID/Investigator# 156
state: Arkansas
city: Irvine
country: United States
facility: Site Reference ID/Investigator# 154
state: California
city: Laguna Hills
country: United States
facility: Site Reference ID/Investigator# 161
state: California
city: Sacramento
country: United States
facility: Site Reference ID/Investigator# 84
state: California
city: Boulder
country: United States
facility: Site Reference ID/Investigator# 119
state: Colorado
city: Miami
country: United States
facility: Site Reference ID/Investigator# 111
state: Florida
city: Tallahassee
country: United States
facility: Site Reference ID/Investigator# 151
state: Florida
city: Atlanta
country: United States
facility: Site Reference ID/Investigator# 108
state: Georgia
city: Atlanta
country: United States
facility: Site Reference ID/Investigator# 109
state: Georgia
city: Northbrook
country: United States
facility: Site Reference ID/Investigator# 105
state: Illinois
city: Indianapolis
country: United States
facility: Site Reference ID/Investigator# 152
state: Indiana
city: Lenexa
country: United States
facility: Site Reference ID/Investigator# 258
state: Kansas
city: Lexington
country: United States
facility: Site Reference ID/Investigator# 261
state: Kentucky
city: Detroit
country: United States
facility: Site Reference ID/Investigator# 116
state: Michigan
city: Traverse City
country: United States
facility: Site Reference ID/Investigator# 158
state: Michigan
city: St. Louis
country: United States
facility: Site Reference ID/Investigator# 124
state: Missouri
city: Henderson
country: United States
facility: Site Reference ID/Investigator# 259
state: Nevada
city: Lebanon
country: United States
facility: Site Reference ID/Investigator# 153
state: New Hampshire
city: Albany
country: United States
facility: Site Reference ID/Investigator# 110
state: New York
city: Charlotte
country: United States
facility: Site Reference ID/Investigator# 117
state: North Carolina
city: Columbus
country: United States
facility: Site Reference ID/Investigator# 113
state: Ohio
city: Dayton
country: United States
facility: Site Reference ID/Investigator# 157
state: Ohio
city: Allentown
country: United States
facility: Site Reference ID/Investigator# 114
state: Pennsylvania
city: Houston
country: United States
facility: Site Reference ID/Investigator# 128
state: Texas
city: Bennington
country: United States
facility: Site Reference ID/Investigator# 155
state: Vermont
city: Greenfield Park
country: Canada
facility: Site Reference ID/Investigator# 132
city: Halifax
country: Canada
facility: Site Reference ID/Investigator# 130
city: Ottawa
country: Canada
facility: Site Reference ID/Investigator# 82
city: Sherbrooke
country: Canada
facility: Site Reference ID/Investigator# 169
city: Vancouver
country: Canada
facility: Site Reference ID/Investigator# 134
city: Frankfurt
country: Germany
facility: Site Reference ID/Investigator# 149
city: Breda
country: Netherlands
facility: Site Reference ID/Investigator# 137
city: Nieuwegein
country: Netherlands
facility: Site Reference ID/Investigator# 148
city: Nijmwegen
country: Netherlands
facility: Site Reference ID/Investigator# 138
city: Sittard
country: Netherlands
facility: Site Reference ID/Investigator# 139
city: Liverpool
country: United Kingdom
facility: Site Reference ID/Investigator# 159
city: London
country: United Kingdom
facility: Site Reference ID/Investigator# 140
city: Newcastle upon Tyne
country: United Kingdom
facility: Site Reference ID/Investigator# 142
city: Nottingham
country: United Kingdom
facility: Site Reference ID/Investigator# 141
city: Oxford
country: United Kingdom
facility: Site Reference ID/Investigator# 144
city: Stoke on Trent
country: United Kingdom
facility: Site Reference ID/Investigator# 143
city: Whitechapel
country: United Kingdom
facility: Site Reference ID/Investigator# 160
Study officials:
affiliation: AbbVie
name: Martin Kaul, MD
role: STUDY_CHAIR
References:
citation: Vollmer TL, Wynn DR, Alam MS, Valdes J. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis. Mult Scler. 2011 Feb;17(2):181-91. doi: 10.1177/1352458510384496. Epub 2010 Dec 6.